ERIS

On January 16, 2026, the Executive Committee of Eris Lifesciences Limited approved the allotment of 23,06,372 equity shares with a face value of Re. 1 each at an issue price of INR 1835.35 per share on a preferential basis to Mr. Naishadh Shah. This issuance was in exchange for his 16,74,493 equity shares (30% stake) in Swiss Parenterals Limited, making Swiss a wholly owned subsidiary of Eris Lifesciences. The paid-up equity capital of the company increased from INR 13,62,16,891 to INR 13,85,23,263. The shares will rank pari-passu with existing equity shares, subject to lock-in and transfer restrictions under SEBI regulations, and will be listed on NSE and BSE upon approval. The company had obtained in-principal approval from NSE and BSE on January 9, 2026, for this preferential issue.